New pill aims to delay dialysis and save hearts in kidney patients
NCT ID NCT07625774
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This large Phase 3 study tests whether the drug HRS-7535 can help people with chronic kidney disease (CKD) avoid serious outcomes like kidney failure, dialysis, or heart-related death. About 3690 adults with CKD will receive either the drug or a placebo, added to their usual care. The goal is to see if HRS-7535 slows kidney decline and lowers cardiovascular risks over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003, China
-
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, 300052, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging kidneys under the microscope: could a simple test predict failure?
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Could a phone app be the key to managing kidney disease?
- A new pill aims to slow kidney failure and save lives
- AI takes on kidney disease: a new model to forecast Who's at risk